Groheux, D., Hindié, E., Delord, M., Giacchetti, S., Hamy, A.S., de Bazelaire, C., de Roquancourt, A., Vercellino, L., Toubert, M.E., Merlet, P. and Espié, M. (2012) Prognostic Impact of (18) FDG-PET-CT Findings in Clinical Stage III and IIB Breast Cancer. Journal of the National Cancer Institute, 104, 1879-1887.
https://doi.org/10.1093/jnci/djs451

has been cited by the following article:

• TITLE: Prognostic Value of SUVmax of 18F-FDG PET/CT in Early Stage Breast Cancer with No LN Metastasis

  AUTHORS: Ryusuke Murakami, Yoshimitsu Fukushima, Hitomi Tani, Kotomi Iwata, Shinichiro Kumita, Maki Nakai, Tomoko Kurita, Keiko Yanagihara, Hiroyuki Takei, Miyuki Matsubara

  KEYWORDS: Breast Cancer, Molecular Subtype, Prognosis, PET/CT, SUVmax

  JOURNAL NAME: Open Journal of Medical Imaging, Vol.7 No.3, September 22, 2017

  ABSTRACT: Purpose: To investigate the correlation between SUVmax of FDG-PET/CT and pathological findings including prognostic factors in early-stage T1-T2 breast cancer patients with no LN metastasis. Materials and Methods: This retrospective study investigated 75 patients (mean age 58.9 years; age range 30 - 82 years) with invasive breast cancer who underwent FDG-PET/CT for preoperative staging. All patients underwent subsequent surgery without prior neoadjuvant chemotherapy or endocrine therapy, and those who were confirmed to have T1- or T2-stage by histopathology with no LN metastasis were included. Two patients who had no perceptible FDG accumulation on PET/CT scans were excluded. The correlations between the SUVmax of the tumor and the pathological and immunohistochemical data were evaluated. Results: The mean SUVmax for the total 73 tumors was 5.46 ± 4.05. The mean SUVmax was 3.95 ± 3.28 for the T1 stage group (n = 36) and 7.23 ± 4.10 (p p p p = 0.008), and high Ki-67 status (p